← back to search

Raed Moh’d Taiseer Al-Rajabi

The University of Kansas Cancer Center · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer Immunotherapy and Biomarkers, and Gastric Cancer Management and Outcomes.
h-index
18
citations
4,480
works
87
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
Annals of Oncology 2022cited by 19position: middledoi
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
Journal of Clinical Oncology 2021cited by 25position: middledoi
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology 2020cited by 1,557position: middledoi
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Journal of Clinical Oncology 2020cited by 1,163position: middledoi
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer
JAMA Network Open 2020cited by 380position: middledoi
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Annals of Oncology 2019cited by 59position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Davide Melisi · State Healthcare Institution "Regional Clinical Oncological Dispensary"4 papers (2019–2022)Christine Lihou · Incyte (United States)4 papers (2019–2022)Efrat Dotan · Diakonessenhuis hospital4 papers (2019–2022)Ghassan K. Abou‐Alfa · Verizon (United States)4 papers (2019–2022)Daniel V.T. Catenacci · University of Chicago4 papers (2019–2022)Antoine Hollebecque · Institut Gustave Roussy4 papers (2019–2022)David Gallinson · Summit Medical Group (United States)4 papers (2019–2022)Adrian Murphy · Johns Hopkins Medicine4 papers (2019–2022)Hui‐Ling Zhen · Huawei Technologies (Sweden)4 papers (2019–2022)Gina M. Vaccaro · Tennessee Oncology4 papers (2019–2022)Luis Féliz · Incyte (United States)3 papers (2019–2021)Do‐Youn Oh · New Generation University College3 papers (2019–2021)Vaibhav Sahai · University of Illinois Urbana-Champaign3 papers (2019–2021)Arndt Vogel · Federal Institute for Risk Assessment3 papers (2019–2021)Eric Van Cutsem · KU Leuven3 papers (2019–2021)Andrew Scott Paulson · Texas Oncology3 papers (2019–2021)Mitesh J. Borad · Mayo Clinic3 papers (2019–2021)Anwaar Saeed · UPMC Hillman Cancer Center1 papers (2020–2020)— · 1 papers (2022–2022)Joaquina Baranda · The University of Kansas Cancer Center1 papers (2020–2020)